Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...
Explore the challenges of accessing timely care and affordable treatments for rare diseases amidst policy shortcomings and ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2025 Earnings Call Transcript January 30, 2026 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.44, expectations were ...
The system enters a field that sees PFA catheters largely displacing thermal modalities for catheter ablation of AF.
CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...
European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...
CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...
The list of medications covered by the Estonian Health Insurance Fund was expanded in January, with new additions including ...
First-of-its-kind, rotation-free single-shot PFA catheter supported by strong safety and efficacy data adds to the groundbreaking Affera family of ...
Affera momentum continues as Medtronic announces CE Mark in Europe & US IDE first cases for Sphere-360 PFA catheter to treat paroxysmal atrial fibrillation: Galway, Ireland Tuesda ...
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent- global net sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results